Zyprexa news | Breaking Zyprexa news

J&J, Bristol-Myers and Amgen on deck

..."Cymbalta is important for their future growth, and it's slowing a bit."LeCroy also said he sees Lilly most lucrative drug, 9, Lilly announced that, due to heightened productivity and increasing sales growth from newer products, it was tweaking its earnings guidance.

The company said it expected fourth-quarter earnings to reach the high end of the 73-to-79-cents-a-share range.

Lilly also said it saw its 2005 adjusted per-share earnings at the top of the $2.80-to-$2.86 range.

Lilly estimated its net income for 2005 at the top of a range of $1.90 to $1.96 a share.

The company expects 2006 earnings of $3.10 to $3.20 a share, excluding any potential one-time charges or gains.The December forecast excluded second-quarter 2005 charges from product litigation over Lilly added that it planned to buy back about $500 million in its own stock.

Please see our Terms of Use.

Disclaimer.

See our Privacy Policy - updated 4/3/03.

CBS and the CBS "eye device" are registered trademarks of CBS Broadcasting, Inc. Intraday data provided by Comstock, a division of Interac...

Zyprexa

News

Advertisers:

J&J, Bristol-Myers and Amgen on deck